skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

With four main drugs competing against each other in the glioblastoma multiforme market it’s vital for those involved to know where they stand. Temodar, Avastin, rindopepimut and DCVax-L are all fighting it out for the highest market share.


Our newest infographic looks at this marketing, in particular highlighting incident cases, product comparisons and sales forecasts for the most successful marketed drug in the market.


Download the infographic today to find out more about this developing area






Download now





電話:+81 (0)3 6273 4260